Pharmaceutical compositions and dosage forms of thalidomide

A thalidomide and dosage form technology, applied in the field of thalidomide pharmaceutical composition and dosage form, can solve problems such as unacceptable thalidomide, inability to ingest diseases, etc.
CN1738607AInactive Publication Date: 2006-02-22CELGENE CORP
3 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CELGENE CORP
Publication Date
2006-02-22
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to provisional application 60 / 426,016, filed November 14, 2002, which is hereby incorporated by reference in its entirety. technical field

[0002] The present invention relates in part to pharmaceutical compositions and dosage forms comprising thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates and clathrates thereof. Background technique

[0003] Thalidomide is a racemic compound commercially available under the trade name THALOMID®, and its chemical name is α-(N-phthalimide) glutarimide or 2-(2,6-dioxo- 3-piperidinyl)-1H-isoindole-1,3-(2H)-dione. Thalidomide was originally developed for the treatment of morning sickness, but it was withdrawn due to tetragenic effects. Thalidomide is currently approved in the United States for the treatment of human erythema nodosum leprosy. Physician's Desk Reftrence(R), 1081-1085 (edition 55, 2001).

[0004] Thalidomide has been reported to be used in patients with le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More